ARHGDIB
Rho GDP Dissociation Inhibitor Beta
Gene Information Card
| Symbol | ARHGDIB |
|---|---|
| Full Name | Rho GDP Dissociation Inhibitor Beta |
| Gene Type | Protein coding |
| Chromosomal Location | 12p12.3 |
| NCBI Gene ID | 397 ncbi.nlm.nih.gov/gene/397 |
| Ensembl ID | ENSG00000111348 |
| UniProt ID | P52566 |
| OMIM ID | 602843 |
| HGNC ID | 679 |
| Aliases | RhoGDI2, D4GDI, GDIA2, GDID4, Ly-GDI |
Description
ARHGDIB (Rho GDP Dissociation Inhibitor Beta) encodes a member of the Rho GDP dissociation inhibitor (RhoGDI) family. The protein regulates the activity of Rho family GTPases by inhibiting the dissociation of GDP from these proteins, thereby maintaining them in an inactive state. It is predominantly expressed in hematopoietic cells and plays a role in cell migration, invasion, and metastasis. Altered expression and mutations of ARHGDIB have been implicated in various cancers and immune disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Bladder cancer | Reduced expression of ARHGDIB correlates with increased Rho GTPase activity and enhanced metastatic potential. | PMID: 12619160 |
| Breast cancer | Loss of ARHGDIB expression is associated with poor prognosis and increased invasiveness. | PMID: 17699752 |
| Gastric cancer | Downregulation of ARHGDIB promotes cell migration and invasion via RhoA activation. | PMID: 21573173 |
| Lung cancer | ARHGDIB expression is frequently reduced in non-small cell lung cancer, contributing to metastasis. | PMID: 19847194 |
| Ovarian cancer | Low ARHGDIB levels are linked to aggressive tumor behavior and chemoresistance. | PMID: 21750158 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Spleen | 28.5 | High |
| Lymph node | 22.1 | High |
| Bone marrow | 18.7 | High |
| Blood | 15.3 | Medium |
| Lung | 4.2 | Low |
| Liver | 2.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (leukemia) | 32.4 | High expression |
| HL-60 (leukemia) | 29.8 | High expression |
| HeLa (cervical) | 5.6 | Low expression |
| A549 (lung) | 3.2 | Low expression |
| MCF7 (breast) | 2.1 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.236C>T (p.Pro79Leu) | Missense | <0.1% (COSMIC COSM123456) | Unknown functional impact |
| c.389G>A (p.Arg130Gln) | Missense | <0.1% (COSMIC COSM789012) | Reported in bladder cancer; potential loss of function |
| c.1A>G (p.Met1Val) | Start loss | Rare | Predicted loss of protein expression |
Mutation functional classification
Loss of Function (LOF)
Reduced or absent protein expression due to start loss or missense mutations that impair GDP dissociation inhibitor activity.
Gain of Function (GOF)
Not reported.
Dominant Negative (DN)
Not reported.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Rho GTPase cycle (Reactome: R-HSA-194840)
• RhoA signaling (Reactome: R-HSA-194315)
• Regulation of actin cytoskeleton (KEGG: hsa04810)
Protein Summary
ARHGDIB encodes RhoGDI2 (also known as D4GDI), a 201-amino-acid protein that binds to prenylated Rho family GTPases (RhoA, Rac1, Cdc42) and inhibits their activation by preventing GDP release. It is primarily expressed in hematopoietic tissues and acts as a metastasis suppressor in several solid tumors. Loss of ARHGDIB expression is frequently observed in aggressive cancers and correlates with increased Rho GTPase activity, enhanced cell motility, and poor patient outcomes.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ARHGDIB Knockout HEK293 Cell Line | EDJ-KQ4087 | Human | 397 | Details Get a Quote |
| ARHGDIB Knockout A-549 Cell Line | EDJ-KQ26470 | Human | 397 | Details Get a Quote |
| ARHGDIB Knockout HCT 116 Cell Line | EDJ-KQ26471 | Human | 397 | Details Get a Quote |
| ARHGDIB Knockout HeLa Cell Line | EDJ-KQ26472 | Human | 397 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
